$622.2 M

FHTX Mkt cap, 20-Nov-2020
Foghorn Therapeutics Net income (H1, 2020)-29.7 M
Foghorn Therapeutics EBIT (H1, 2020)-29.3 M
Foghorn Therapeutics Cash, 30-Jun-202036.6 M
Foghorn Therapeutics EV636.1 M

Foghorn Therapeutics Income Statement

Annual

USDFY, 2018FY, 2019

R&D expense

21.2m44.4m

General and administrative expense

4.8m6.7m

Operating expense total

26.0m51.1m

EBIT

(26.0m)(51.1m)

Interest expense

371.0k540.0k

Net Income

(26.3m)(51.1m)

EPS

(8.9)(12.2)

Half Year

USDH1, 2019H1, 2020

R&D expense

19.6m25.1m

General and administrative expense

3.2m4.1m

Operating expense total

22.8m29.3m

EBIT

(22.8m)(29.3m)

Interest expense

249.0k456.0k

Net Income

(22.7m)(29.7m)

EPS

(5.9)(5.6)

Foghorn Therapeutics Balance Sheet

Annual

USDFY, 2018FY, 2019

Cash

40.0m15.0m

Current Assets

40.4m16.9m

PP&E

2.1m2.7m

Total Assets

43.1m22.3m

Accounts Payable

2.0m3.4m

Short-term debt

1.4m

Current Liabilities

3.5m12.7m

Long-term debt

157.0k

Total Debt

1.5m

Total Liabilities

11.1m23.8m

Preferred Stock

71.3m86.5m

Additional Paid-in Capital

3.7m6.1m

Retained Earnings

(43.0m)(94.1m)

Total Equity

(39.3m)(88.0m)

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0.1 x

Financial Leverage

-1.1 x-0.3 x

Quarterly

USDQ2, 2020

Cash

36.6m

Current Assets

39.0m

PP&E

8.2m

Total Assets

94.3m

Accounts Payable

3.0m

Short-term debt

380.0k

Current Liabilities

15.9m

Long-term debt

50.1m

Total Debt

50.5m

Total Liabilities

76.2m

Common Stock

1.0k

Preferred Stock

134.5m

Additional Paid-in Capital

7.4m

Retained Earnings

(123.8m)

Total Equity

(116.4m)

Debt to Equity Ratio

-0.4 x

Debt to Assets Ratio

0.5 x

Financial Leverage

-0.8 x

Foghorn Therapeutics Cash Flow

Annual

USDFY, 2018FY, 2019

Net Income

(26.3m)(51.1m)

Depreciation and Amortization

379.0k693.0k

Accounts Payable

1.3m1.2m

Cash From Operating Activities

(22.6m)(46.3m)

Purchases of PP&E

(1.5m)(968.0k)

Cash From Investing Activities

(1.5m)(968.0k)

Cash From Financing Activities

51.8m24.0m

Net Change in Cash

27.6m(23.3m)

Interest Paid

211.0k420.0k

Quarterly

USDQ2, 2019Q2, 2020

Net Income

(22.7m)(29.7m)

Depreciation and Amortization

290.0k509.0k

Accounts Payable

1.1m(285.0k)

Cash From Operating Activities

(20.9m)(23.4m)

Purchases of PP&E

(794.0k)(3.3m)

Cash From Investing Activities

(794.0k)(3.3m)

Cash From Financing Activities

15.3m48.2m

Net Change in Cash

(6.3m)21.6m

Interest Paid

216.0341.0k

Foghorn Therapeutics Ratios

USDFY, 2018

Financial Leverage

-1.1 x

Foghorn Therapeutics Operating Metrics

Q2, 2020

Discovery Stage Products

3

IND-Enabling Stage Products

2